Previous 10 | Next 10 |
home / stock / lmllf / lmllf news
Toronto, Ontario--(Newsfile Corp. - January 13, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabi...
Toronto, Ontario--(Newsfile Corp. - December 13, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cann...
Established alignment with FDA on the path forward for the development of PD-001, a patented enteric-coated formulation of cepharanthine, towards clinical studies for mild-moderate COVID-19 infection Meeting response validates CMC package for PD-001 as an oral anti-viral to treat COVID-19...
Results of the 4 cancer types where cepharanthine provides exceptional potency and/or synergistic inhibitory effects when combined with standard of care (SoC) chemotherapy provides support for next development stage Advancing Cepharanthine (PD-001) to IND-enabling efficacy studies to supp...
PharmaDrug narrows list of candidate tryptamine molecules for the treatment of primary open angle glaucoma (PAOG) Terasaki Institute receives PharmaDrug's two candidate DMT analogue molecules Terasaki Institute, initiates supportive IND-enabling mechanism of action studies to evalua...
Toronto, Ontario--(Newsfile Corp. - November 1, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedel...
Toronto, Ontario--(Newsfile Corp. - October 20, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedel...
Cepharanthine reproducibly demonstrates potential as a monotherapy in treating multiple cancers with unsatisfactory treatment options Identified 4 cancer types where cepharanthine provides additive or synergistic inhibitory effects when combined with standard of care (SoC) chemotherapy ...
Toronto, Ontario--(Newsfile Corp. - September 28, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, ...
Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company ") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psych...
News, Short Squeeze, Breakout and More Instantly...
2024-05-23 11:51:50 ET This company believes that the only viable way to produce a safe supply of street drugs is to develop biosynthetic versions of these substances to be manufactured domestically in a regulated %Pharmaceutical supply chain. The signing of a recent LOI could potential...
Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved...
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent ...